Senores Pharmaceuticals IPO Details, Price Band, Lot Size, GMP

The much-awaited Initial Public Offering (IPO) of Senores Pharmaceuticals Ltd is going to be open for public subscription from this Friday, December 20, 2024. As it has planned to garner more than ₹582 crore, the mainboard IPO is buzzing among investors.  Here's everything you need to know.

💊 Senores Pharmaceuticals Limited IPO

🗓️Date:   20 - 24 Dec,2024

🏷️Price Band : ₹372- ₹391

📦Market Lot:  38 Shares

💰Application Amount: ₹14,858

📏Size : ₹582.11 Cr Approx

👦Retail Portion:10%

📃 Retail Form: 38,981

📄HNI Small Form: 1,392

📄HNI Big Form: 2,784

🏷️Face Value: ₹10

The IPO of Senores Pharmaceuticals will remain open from 20 December to 24 December 2024. The price band has been fixed between ₹372 and ₹391 per share, giving an opportunity to investors to buy equity in a leading pharmaceutical company. At the upper price band, the IPO size is estimated at ₹582.11 crore, comprising a fresh issue of 1.28 crore equity shares worth ₹500 crore, and an offer-for-sale (OFS) of 21 lakh equity shares amounting to ₹82.11 crore.

Key Dates of Senores Pharmaceutical Limited IPO

The IPO's minimum lot size is 38 shares, thereby necessitating a retail investor to invest at least ₹14,858. Some of the prominent promoters such as Swapnil Shah, Ashokkumar Barot, and Sangeeta Barot will offload 11 lakh equity shares under the OFS while key shareholder Prakash M Sanghvi will sell 10 lakh shares.

Promoter and OFS Details for Senores Pharmaceutical Limited IPO

Senores Pharmaceuticals has planned the net proceeds of the offering to invest in its subsidiary operations, prepay or retire certain borrowings, finance working capital, support acquisition-driven inorganic growth, and for general corporate purposes. As such, it reflects how the company has always strategically thought to fortify the domestic markets and the international ones.

The IPO reservation structure is designed to offer 75 percent shares to Qualified Institutional Buyers, 15 percent to Non-Institutional Investors, and 10 percent to retail investors. The shares are expected to be allotted by December 26, 2024. The listing is expected to be on the BSE and NSE on December 30, 2024.

Investor Reservation for Senores Pharmaceutical Limited IPO

Company Details of Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Ltd is a global pharmaceutical development company that targets regulated as well as emerging economies. A diversified portfolio includes 55 product offerings in major therapeutic fields from September 30, 2024: antibiotics/antifungals amongst its offerings. A diversified strong product portfolio provides the drug discovery entity with a formidable position in the global arena of a developing industry.

There is tremendous interest in the IPO, going by the GMP. The GMP stands at a decent ₹150 per share, which means shares are being traded at ₹541 in the grey market. This is a 38.36% premium over the upper price band of ₹391.

Financial Details of Senores Pharmaceutical Limited

Registrar Contact Details of Senores Pharmaceutical Limited

Link Intime India Private Ltd

Phone: +91-22-4918 6270

Email: senorespharma.ipo@linkintime.co.in

Website: https://linkintime.co.in/initial_offer/public-issues.html

Why Invest in Senores Pharmaceuticals IPO?

There are several reasons the investors are attracted to the IPO.

• It will come forth in controlled markets, signifying it to be credible and growth-ready. The company has an effective product portfolio, with diversified, high-demand pharmaceutical products, and this also helps the investor gain confidence.
• The usage of funds: This is being utilized for expansion, debt reduction, and strategic acquisition, signifying the prospect of long-term growth.

The Senores Pharmaceuticals IPO holds an interesting investment opportunity founded on a strong market presence and a diverse portfolio of products along with well-defined growth strategies. It will be open to subscription from December 20 through December 24, 2024, and is to be listed on December 30, 2024. Thus, this IPO will attract serious attention from both institutional investors and retail investors. Do not pass up this opportunity to put your money into one of the most promising pharmaceutical companies of the year.